The Phase IIb failure of Teva Pharmaceutical Industries Ltd./Xenon Pharmaceuticals Inc.’s TV-45070 pain ointment in osteoarthritis is another blow for the once very promising Nav1.7 target, but some consultants advise not to rule the class out yet in other indications.
Teva/Xenon’s Pain Ointment Failure Leaves Sparser Nav1.7 Pipeline
Once highly anticipated as an alternative mechanism for pain, the Nav1.7 target suffered another blow with Teva/Xenon’s failure of TV-45070 in osteoarthritis, though the class may still work in neuropathic pain.
More from Clinical Trials
• By
Newly published insights from a series of European Medicines Agency workshops can guide drug developers in designing development plans that meet the needs of both regulators and health technology assessment bodies.
• By
The new global GCP guideline, ICH E6(R3), enables researchers and clinical trial administrators to tailor their documentation processes, but also opens the door for more scrutiny during GCP inspections.
• By
The European Medicines Agency’s qualification of the AIM-NASH tool is said to signify a major advancement for clinical trials for metabolic dysfunction-associated steatohepatitis. The market size for MASH treatments is expected to grow substantially in the coming years.
• By
As Indian CROs are bracing for new registration mandates, an expert panel at the IGBA’s 3rd Bioequivalence conference discusses the implications of non-compliance in bioequivalence studies.
More from R&D
• By
As Indian CROs are bracing for new registration mandates, an expert panel at the IGBA’s 3rd Bioequivalence conference discusses the implications of non-compliance in bioequivalence studies.
• By
Experts working in the advanced therapy space say the US has less strict criteria for regulatory pathways for cell and gene therapies than the EU, particularly for products in early development.
• By
Japan adds four new pediatric vaccines, including for MMRV and norovirus, to a list of priority vaccines eligible for assistance in regulatory processing.